Cargando…

DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report

5-Fluorouracil remains a foundational component of chemotherapy for solid tumour malignancies. While considered a generally safe and effective chemotherapeutic, 5-fluorouracil has demonstrated severe adverse event rates of up to 30%. Understanding the pharmacokinetics of 5-fluorouracil can improve t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wigle, Theodore J., Tsvetkova, Elena V., Welch, Stephen A., Kim, Richard B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572291/ https://www.ncbi.nlm.nih.gov/pubmed/31052357 http://dx.doi.org/10.3390/pharmaceutics11050199

Ejemplares similares

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy
por: Amstutz, Ursula, et al.
Publicado: (2008)

Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil
por: Winquist, Lauren E., et al.
Publicado: (2020)

Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients
por: Savva-Bordalo, Joana, et al.
Publicado: (2010)

Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
por: Hishinuma, Eiji, et al.
Publicado: (2022)

Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant
por: Majounie, Elisa, et al.
Publicado: (2020)

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)

Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
por: Li, Qiang, et al.
Publicado: (2014)

Retracted: Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
por: Research and Practice, Gastroenterology
Publicado: (2020)

Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study
por: Miarons, Marta, et al.
Publicado: (2023)

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature
por: White, Cassandra, et al.
Publicado: (2021)

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
por: Iachetta, Francesco, et al.
Publicado: (2019)

Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays
por: De Luca, Ottavia, et al.
Publicado: (2022)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes
por: Saif, Muhammad W, et al.
Publicado: (2016)

Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping
por: Morelli, Cristina, et al.
Publicado: (2022)

97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing
por: Varughese, Lisa A., et al.
Publicado: (2021)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
por: Ragia, Georgia, et al.
Publicado: (2023)

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
por: De Falco, Vincenzo, et al.
Publicado: (2019)

A Case of Neurotoxicity Following 5-Fluorouracil-based Chemotherapy
por: Ki, Seung Seog, et al.
Publicado: (2002)

Frequency of the DPYD * 2A allele in the Czech population
por: Koudová, Monika, et al.
Publicado: (2014)

Onychomadesis associated with chemotherapy: case report and mini literature review
por: Li, Ang, et al.
Publicado: (2017)

Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5-FU Chemotherapy in a Saudi Patient
por: Bukhari, Nedal, et al.
Publicado: (2019)

Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients
por: Negarandeh, Reza, et al.
Publicado: (2020)

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
por: Deng, Xunwei, et al.
Publicado: (2020)

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
por: Del Re, Marzia, et al.
Publicado: (2019)

Mutations at codon 974 of the DPYD gene are a rare event.
por: Ridge, S. A., et al.
Publicado: (1997)

Mutations at codon 974 of the DPYD gene are a rare event.
por: Diasio, R. B., et al.
Publicado: (1997)

A Case of Wernicke's Encephalopathy Following Fluorouracil-based Chemotherapy
por: Cho, In Jeong, et al.
Publicado: (2009)

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
por: Ockeloen, Charlotte W, et al.
Publicado: (2021)

New advances in DPYD genotype and risk of severe toxicity under capecitabine
por: Etienne-Grimaldi, Marie-Christine, et al.
Publicado: (2017)

Implementation and clinical benefit of DPYD genotyping in a Danish cancer population
por: Paulsen, N.H., et al.
Publicado: (2023)

Influence of DPYD*9A, DPYD*6 and GSTP1 ile105val Genetic Polymorphisms on Capecitabine and Oxaliplatin (CAPOX) Associated Toxicities in Colorectal Cancer (CRC) Patients
por: K, Ashok Varma, et al.
Publicado: (2019)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report
por: Mukherji, Deborah, et al.
Publicado: (2019)

Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy
por: Yi, Hee Jung, et al.
Publicado: (2016)

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2018)

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
por: Maslarinou, Anthi, et al.
Publicado: (2023)

A Case of Severe Coronary Spasm Associated with 5-Fluorouracil Chemotherapy
por: Kim, Sang-Min, et al.
Publicado: (2012)

Elevated Risk of Fluoropyrimidine-Associated Toxicity in European Patients with DPYD Genetic Polymorphism: A Systematic Review and Meta-Analysis
por: Kim, Woorim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a6lj4mu90frne53l6tooagcmhk